The EPS projection of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for quarter ended 2016-09-30 is $-0.73. A week before, the EPS forecast was $-0.73 against target of $-0.73, a month earlier. This estimate stood at $-0.73 60 days earlier versus forecast of $-0.73 90 days earlier, confirming a deviation of 0%.
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 3.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 0, 0 and 0, respectively.
The downgrade of EPS estimates for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) in the preceding 120, 60, 30 and 90 days were 1, 3, 1 and 3, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) was $-0.73. This projection was computed after accounting 4 calls. As reported on 2016-05-05 the EPS was $-0.9. The change was $-0.19, demonstrating a percentage deviation of -26.76%. The projections confirmed a standard deviation of 0.18.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) stands at $7.175 and the median estimate at $7.175. Almost 2 analysts announced their estimates.
The highest estimate is $9.45 while the lowest target is $4.9 showing standard deviation of 3.217%.
As many as 2 analysts released sales estimates reised in upside while 2 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 2 revised sales number projection on upside while 2 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 2 hiked sales estimations and 2 reduced sales forecast. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) stated that the change in forecast was -20.936%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...